Compare

Genmab A/S/DKr GMAB

1D1W1M3M6MYTD1Y5YMAX

About Genmab A/S

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.
Ticker
DKr GMAB
Sector
Health
Primary listing
CSE
Employees
3,119
Headquarters
Copenhagen, Denmark
Website
www.genmab.com

Genmab A/S Metrics

BasicAdvanced
kr 157B
31.27
kr 84.11
0.69
-

What the Analysts think about Genmab A/S

Analyst ratings (Buy, Hold, Sell) for Genmab A/S stock.
Analyst projections of the future price of Genmab A/S stock.

Bulls say / Bears say

First-half revenue rose 25% to $2.05 billion, and Genmab raised its 2026 revenue and operating-profit outlook. That gives the company stronger near-term earnings momentum. (Genmab)
EPKINLY sales grew 48% in the first half, and EU approval of its combination with lenalidomide and rituximab opens a further market in relapsed or refractory follicular lymphoma. This supports growth from Genmab’s commercial portfolio beyond royalties. (Genmab, GlobeNewswire)
A Phase 3 trial of epcoritamab with R-CHOP in newly diagnosed DLBCL met its primary endpoint, cutting the risk of progression or death by 51%. If regulators approve the combination, it could extend the drug into an earlier treatment setting. (AbbVie)
Genmab’s 2026 outlook relies heavily on DARZALEX royalties, while its investor presentation says those royalties are due to end in the US in 2029 and elsewhere in 2031. A weaker DARZALEX franchise or the expiry could leave a large revenue gap to fill. (Genmab, MarketScreener)
The Merus acquisition has left Genmab with $5.1 billion in borrowings. First-half operating cash flow fell to $54 million from $349 million a year earlier, while interest expense was $174 million, limiting financial flexibility. (StockTitan)
Rina-S still faces pivotal trial readouts, and Genmab’s management has acknowledged that the folate-receptor ADC field is crowded with larger competitors. Delays or weaker results could make it harder to turn the late-stage pipeline into the growth needed to offset future royalty declines. (Exa, Genmab)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.

Genmab A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Genmab A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Genmab A/S

AllUSDEURGBP
Funds
Fund name
Fund size
DKr GMAB weighting
iShares Healthcare Innovation$HEAL
$1.3B1.87%
iShares Healthcare Innovation€2B78
$1.2B1.87%
iShares Healthcare Innovation£DRDR
$1.3B1.87%
Xtrackers MSCI Nordic£XDN0
€1.1B1.58%
iShares STOXX Europe 600 Health Care€EXV4
€709M1.27%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.